A Phase II randomized, open label non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy
A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib versus Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Following a Front-Line Complete Cytoreduction Surgery
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.MK-2870/022-PARPi (EvoPAR Ovarian01)
“Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy.GINECO/MK-2870-021
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer.DESTINY-OVARIAN 01
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.
“A Phase 2 study evaluating the efficacy and safety of TORL-1-23 in Women with advanced platinum-resistant epithelial ovarian cancer (including primary peritoneal and fallopian tube cancers) expressing Claudin 6 (CLdn6)” NOGGO/TORL
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Phase III, multi-center, randomized (1:1), open label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy (wPac or PLD), in participants with no germline BRCA mutation detected, platinum-resistant or refractory, HGSOC
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of patients with recurrent ovarian cancer not suitable for platinum treatment (ROC-NP)
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)”
“A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer”RAINFOL-OV2
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
A randomized, open label, phase II trial of Anti-PD1, dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation
PI: Antonio González
CoPI: Jerónimo Martínez García
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Metastatic or Recurrent Cervical Cancer”
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer”
Estudio de fase II, aleatorizado y doble ciego que compara el tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2 de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante
A phase III, Randomized, Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus treatment of Physician´s choice in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer who progress after Platinum-based Chemotherapy and Anti PD-1/anti-PD-L1 therapy
“A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent or metastatic endometrial cancer.”
An Open label, Randomized, Multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+/IHC 2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer”(DESTINY)
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan versus Standard of Care (Carboplatin in Combination with Paclitaxel) as Adjuvant Treatment for HER2-expressing (IHC 3+/IHC 2+) Endometrial Cancer
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy
“A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer
A PHASE 3, Randomized, placebo-controlled, Double-Blind, multicenter Trial of selinexor in Maintenance therapy After systemic therapy for Patients with P53 Wild-TYPE, Advanced or Recurrent Endometrial carcinoma
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting)
“A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Recurrent or Advanced Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy”
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
A phase 3, randomized, double blind multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus placebo plus Carboplatin-Paclitaxel in patients with recurrent or primary advance endometrial cancer
A Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. A Phase II, multicenter, prospective, open-label, randomized, controlled study.
An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL
An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL
Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
Phase III study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.
Phase II study Carbo + DLP or paclitaxel with or without farletuzumabplatinum resistant relapses with low levels of CA 125.
Closed
Ovarian cancer
ENGOT-ov26/GEICO 54-O/PRIMA
PI: Antonio González
A Phase 3 Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.
Estudio retrospectivo sobre tratamiento del cáncer de ovario.
Closed
Ovarian cancer
GEICO 44-R/RETRO-ROC
PI: I. Romero
Estudio post-autorización observacional restrospectivo y multicéntrico de la combinación con trabectedina y doxorubicinaliposomalpegilada (DLP) en cáncer de ovario recidivante.
CÓDIGO DE ENSAYO CLÍNICO: GEICO 1302 - ENGOT OV 11 - Array 162-311
PI: I. Romero
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Closed
Ovarian cancer
CÓDIGO DE ENSAYO CLÍNICO: GEICO 1303-ENGOT OV 16- NOVA (ENGOT)
PI: JM. Del Campo
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
Closed
Ovarian cancer
ENGOT-OV-2b/TRINOVA 3/GEICO-1201
PI: JM. Del Campo
TRINOVA – A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
Closed
Ovarian cancer
MM-121/GEICO 1202
PI: Antonio González, Andrés Redondo, JM. Rubio, A. Poveda
Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers.
Closed
Ovarian cancer
NCIC-OV 21/GEICO-0902
PI: I. Romero, J. Ponce
Estudio de Fase II-III de quimioterapia intraperitoneal (IP) más intravenosa (IV) frente a carboplatino más Paclitaxel IV en pacientes con carcinoma epitelial de ovario sometidas a cirugía citoreductora óptima posterior a quimioterapia intravenosa neoadyuvante.
Closed
Ovarian cancer
GEICO 1001-CATUMAXOMAB
PI: Ana Oaknin
Ensayo Fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidación de pacientes con un carcinoma epitelial de ovario, de trompa de Falopio, o un carcinoma primario peritoneal en segunda o tercera remisión completa clínica.
Closed
Ovarian cancer
AGO-OVAR 12/GEICO 1003
PI: JM. Del Campo
Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con carboplatino y paclitaxel en pacientes con cáncer de ovario avanzado.
Closed
Ovarian cancer
GEICO 1002
PI: Ana Oaknin
Ensayo clínico fase II no controlado, multicéntrico y prospectivo para determinar el beneficio clínico y toxicidad de Pazopanib, inhibidor multidiana de receptores con actividad tirosin-quinasa (VEGFR -1, -2 , -3, PDGFR-α y β y C-Kit), en pacientes con cáncer de ovario avanzado platino resistentes.
Closed
Ovarian cancer
ICON-6/GEICO 1101
PI: Antonio González
Ensayo clínico multicéntrico del Gynaecologic Cancer Intergroup, controlado doble ciego de Cediranib (AZD 2171), en combinación con quimioterapia basada en platino y como agente único en terapia de mantenimiento, en mujeres con cáncer de ovario que han recaído más de 6 meses tras la finalización de un tratamiento de primera línea basado en platino.
Closed
Ovarian cancer
AURELIA/GEICO 0904
PI: A. Poveda
AURELIA: Ensayo clínico de fase III multicéntrico, abierto, aleatorizado, con dos grupos de tratamiento, de bevacizumab en combinación con quimioterapia frente a quimioterapia sola en pacientes con cáncer epitelial de ovario, carcinoma de trompas de Falopio o peritoneal primario resistente a platino.
Closed
Ovarian cancer
GEICO 0901/AGO-OVAR 16
PI: JM del Campo
Estudio de fase III para evaluar la eficacia y la seguridad de pazopanib en monoterapia frente a placebo entre mujeres con cáncer epitelial de ovario, de trompa de Falopio o peritoneal primario que no hayan progresado después de la quimioterapia de primera línea.
Closed
Ovarian cancer
GEICO 0905-OCTAVIA
PI: Antonio González
A single-arm Phase II clinical study of the combination of carboplatin and weekly periclitar plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer.
Closed
Ovarian cancer
GEICO 0802/HECTOR-PHASE III-2006
PI: Antonio González, A. Santaballa
Topotecán más carboplatino frente al tratamiento estándar (paclitaxel más carboplatino o gemcitabina más carboplatino) en el tratamiento de pacientes con carcinoma peritoneal, carcinoma de trompas o carcinoma epitelial de ovario plantino-sensibles recidivantes.
Closed
Ovarian cancer
GEICO 0804-R
PI: B. Ojeda
Base de datos de Bevacizumab en recaídas de Cáncer de Ovario.
Closed
Ovarian cancer
GEICO 0801-T
PI: A. Poveda
Estudio retrospectivo de biomarcadores en Cáncer Epitelial de Ovario.
Closed
Ovarian cancer
GEICO 0803-R
PI: Ana Oaknin
Feasibility and toxicity of a modified outpatient regimen of intravenous/ intraperitoneal chemotherapy (IV/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study.
Closed
Ovarian cancer
GEICO 0701/ICON-7
PI: A. Cervantes
Estudio aleatorizado del “Gynaecologic Cancer InterGroup”, de dos grupos, multicéntrico para añadir bevacizumab a la quimioterapia estándar (carboplatino y paclitaxel) en pacientes que sufren cáncer epitelial de ovario.
Closed
Ovarian cancer
GEICO 0702-T/TOPO IIA
PI: Antonio González
Determinación de la expresión de TOPO IIA en muestras de carcinoma de ovario de pacientes tratadas con doxorubicina liposomal pegilada.
Closed
Ovarian cancer
GEICO 0703/MIMOSA
PI: A. Casado
Ensayo clínico multicéntrico aleatorizado, doble ciego, controlado con placebo, para evaluar el tratamiento de mantenimiento con abagovomab en pacientes afectas de carcinoma epitelial ovárico tras respuesta completa a la quimioterapia de la First - line.
Closed
Ovarian cancer
GEICO 0104
PI: Antonio González
Estudio fase II randomizado del doblete carboplatino-gemcitabina seguido de carboplatino paclitaxel versus carboplatino-paclitaxel en pacientes con recidiva platinosensible de carcinoma de ovario, carcinomatosis peritoneal primaria o carcinoma de trompa.
Closed
Ovarian cancer
GEICO 0101
PI: MA. Izquierdo, A. Cervantes
Ensayo clínico de fase III para evaluar el tratamiento con la combinación cisplatino más topotecán seguido de paclitaxel más carboplatino frente a paclitaxel más carboplatino como tratamiento de primera línea en mujeres con un diagnóstico reciente de cáncer epitelial de ovario avanzado.
Closed
Ovarian cancer
GEICO 0103
PI: B. Ojeda
Estudio fase II, con Gemcitabina en infusión prolongada en pacientes con cáncer epitelial de ovario avanzado resistentes a platino
Closed
Ovarian cancer
GEICO CO22
PI: A. Casado
Validación por GEICO de CAELYX en pacientes con cáncer epitelial de ovario.
Closed
Ovarian cancer
GEICO 0199
PI: Antonio González
Ensayo clínico fase II randomizado (con valoración de calidad de vida) de carboplatino frente a la combinación de taxol y carboplatino en pacientes con recaída de cáncer de ovario platino-sensible.
Closed
Ovarian cancer
GEICO 0299/EORTC 55981/NSGO
PI: MA. Izquierdo, JM del Campo
Ensayo Clínico aleatorizado de Paclitaxel / Epirubicina / Carboplatino en combinación (TEC) vs Paclitaxel / Carboplatino (TC) en el tratamiento de mujeres con cáncer de ovario avanzado.
Closed
Ovarian cancer
ENGOT-ov60/GEICO 98-O/Ramp 201
PI: Ana Oaknin
CoPI: Alejandro Pérez Fidalgo
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
Multicentric Single arm Phase II clinical trial, to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients
A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study
Closed
Ovarian cancer
ENGOT-ov25/GEICO 48-O/PAOLA
PI: Antonio González / Raúl Marquez
Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance
A Phase III study of Atezolizumab versus Placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with new diagnosed stage III/stage IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
A phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.
Atezolizumab in combination with Bevacizumab +/- Chemotherapy versus Chemo-BEV standard in recurrent ovarian cancer – a randomised trial
Closed
Ovarian cancer
ENGOT-ov41/GEICO 69-O/ANITA
PI: Antonio González
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
Closed
Ovarian cancer
ENGOT-ov46/GEICO 76-O/DUO-O
PI: Mª. Jesús Rubio
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients
Closed
Ovarian cancer
ENGOT-ov44/GEICO 77-O/FIRST
PI: Andrés Redondo
CoPI: Lydia Gaba
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Cancelled
Ovarian cancer
ENGOT-ov73/GEICO 123-O/LUPPA-1
PI: Antonio González
CoPI: Luis Manso
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin in Combination with Paclitaxel vs. Platinum-based Chemotherapy or Weekly Paclitaxel as Treatment in Patients with Relapsed Platinum-sensitive Ovarian Cancer
Cancelled
Ovarian cancer
ENGOT-ov71/GEICO 121-O/UP-NEXT
PI: Antonio González
CoPI: Marga Romero
Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive, High-grade Serous Ovarian Cancer
Cancelled
Ovarian cancer
ENGOT OV75/ GEICO 128-O/INNOVATE 5
PI: Margarita Romero Martín
CoPI: Gloria Marquina
A Pivotal, Randomized Controlled, Open-Label Study of Tumor Treating Fields (TT Fields) in Patients with Recurrent Ovarian Cancer in Whom Platinum Is an Option
Cancelled
Ovarian cancer
ENGOT gyn2/GEICO 97-O/BOUQUET
PI: Andrés Redondo
A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors.
Cancelled
Ovarian cancer
ENGOT ov79/GEICO 134-O/STRO-002-GM3 (REFRaME-01)
PI: Ana Oaknin
A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)
Closed
Cervical cancer
ENGOT-Cx6/GEICO 73-C
PI: Antonio González
A Phase 2 Trial of TisotumabVedotin (HuMax®-TF- ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer.
Closed
Cervical cancer
ENGOT-CX1/GEICO 43-O
PI: MJ Rubio
Estudio de fase II, de tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante.
Fase II carbo-paclitaxel-bevacizumab en primera línea del carcinoma de cérvix persistente, recurrente o diseminado.
Closed
Cervical cancer
GOG-0240 / GEICO-0903
PI: Ana Oaknin
Ensayo en Fase III aleatorizado de Cisplatino más Paclitaxel con y sin Bevacizumab frente al doblete sin platino, Topotecan más Paclitaxel, con y sin Bevacizumab, en carcinoma de cérvix en estadio IVB, recurrente o persistente.
Closed
Cervical cancer
GEICO 2005/01
PI: MJ Rubio
Estudio exploratorio fase II para evaluar la eficacia y seguridad de topotecan semanal en el tratamiento de cáncer de cérvix persistente o recidivante tras fracaso de tratamiento de primera línea con derivados del platino.
Closed
Cervical cancer
ENGOT-cx9/GEICO 72-C/EMPOWER Cx-1 // REGENERON
PI: Ana Oaknin
Randomized, open-label, phase III clinical trial of REGN2810 compared to investigator's choice chemotherapy treatment for recurrent or metastatic platinum-resistant cervical carcinoma
Estudio de fase II, aleatorizado y doble ciego que compara el tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2 de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante
A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
A phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.
Yondelis en leiomiosarcoma uterino: estudio retrospectivo + biomarcadores.
Closed
Endometrical cancer
GEICO P02868/GEIS 7
PI: Andrés Poveda
Ensayo Fase IV-II de Temozolamida en esquema de administración oral continua en el tratamiento de los Sarcomas Ginecológicos.
Closed
Endometrical cancer
ENGOT-en5/GEICO 67-E/SIENDO
PI: Alejandro Pérez Fidalgo
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
A PHASE II MULTICENTER, OPEN-LABEL, SINGLE ARM TRIAL OF AVELUMAB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT/METASTATIC ENDOMETRIAL CANCER
Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma
A Phase 3, Randomized, Double‐Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High‐Risk Endometrial Cancer After Surgery With Curative Intent “
We use our own and third party cookies for the correct operation, display and use of the website by the user and to improve our services by collecting statistical data on the navigation of users on the website. You can learn more about the cookies we use and even reject them by viewing our Cookies Policy. By pressing the 'Accept' button you consent to the use of the above cookies.
Functional
Always active
The storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or solely for the purpose of carrying out the transmission of communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The storage or technical access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles for sending advertising, or to track the user across one or more websites for similar marketing purposes.
